These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27330257)

  • 21. Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review.
    Roger C
    J Intensive Med; 2024 Jul; 4(3):287-298. PubMed ID: 39035618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.
    Smits A; De Cock RF; Allegaert K; Vanhaesebrouck S; Danhof M; Knibbe CA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6344-51. PubMed ID: 26248375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation.
    Touchard C; Aubry A; Eloy P; Bréchot N; Lebreton G; Franchineau G; Besset S; Hékimian G; Nieszkowska A; Leprince P; Luyt CE; Combes A; Schmidt M
    Crit Care; 2018 Aug; 22(1):199. PubMed ID: 30121083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing.
    Chiriac U; Richter DC; Frey OR; Röhr AC; Helbig S; Preisenberger J; Hagel S; Roberts JA; Weigand MA; Brinkmann A
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study.
    Roger C; Louart B; Elotmani L; Barton G; Escobar L; Koulenti D; Lipman J; Leone M; Muller L; Boutin C; Amour J; Banakh I; Cousson J; Bourenne J; Constantin JM; Albanese J; Roberts JA; Lefrant JY;
    Ann Intensive Care; 2021 Mar; 11(1):49. PubMed ID: 33740157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered Pharmacokinetics in Prolonged Infusions of Sedatives and Analgesics Among Adult Critically Ill Patients: A Systematic Review.
    Tse AHW; Ling L; Lee A; Joynt GM
    Clin Ther; 2018 Sep; 40(9):1598-1615.e2. PubMed ID: 30173953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of anti-infective agents in critically ill patients.
    Jager NG; van Hest RM; Lipman J; Taccone FS; Roberts JA
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):961-79. PubMed ID: 27018631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients.
    Blackburn LM; Tverdek FP; Hernandez M; Bruno JJ
    Int J Antimicrob Agents; 2015 Jan; 45(1):46-53. PubMed ID: 25455848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appropriateness of gentamicin therapeutic drug monitoring at a Middle Eastern tertiary hospital setting: a retrospective evaluation and quality audit.
    Al-Sulaiti FK; Alkhiyami D; Elmekaty EZI; Awaisu A; Kheir N; El-Zubair A; Al-Sulaiti HK
    J Pharm Policy Pract; 2024; 17(1):2375753. PubMed ID: 39011355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.
    Póvoa P; Moniz P; Pereira JG; Coelho L
    Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34203510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
    Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critically-ill patients receiving total parenteral nutrition show altered amikacin pharmacokinetics.
    Tormo C; Abad FJ; Ronchera-Oms CL; Parra V; Jiménez NV
    Clin Nutr; 1995 Aug; 14(4):254-9. PubMed ID: 16843940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.